SLAMF7 improves the efficacy of PD-1 immunotherapy by enhancing T cell response in non-small cell lung cancer

Programmed death-1 (PD-1) immune checkpoint inhibition has transformed the therapeutic landscape of non-small cell lung cancer (NSCLC), while a proportion of NSCLC cases exhibited primary or acquired resistance, reflecting the imperative to elucidate resistance mechanisms and identify synergistic im...

全面介紹

書目詳細資料

Principais autores:	Juanfeng Lao, Manman Zhu, Liangjian Kuang, Changliang Luo, Zhongyuan Lin, Qiongying Ling, Yulin Yuan, Yongjian Wu, Liuyang Shu
格式:	Artigo
語言:	Inglês
出版:	Elsevier 2026-01-01
叢編:	Immunobiology
主題:	SLAMF7 PD-1 Combination immunotherapy NSCLC
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S017129852600001X
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!